Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension: Effects of angiotensin converting enzyme inhibition

Journal of Hypertension

Volumn 16, Issue 6, 1998, Pages 863-870

  Laviades, Concepción ^d   Gil, María J ^a   Monreal, Ignacio ^a   González, Arantxa ^b,c   Díez, Javier ^b,c  

^a University Clinic   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d 'San Jorge' General Hospital   (Spain)

Author keywords

Essential hypertension; Insulin resistance; Insulin like growth factor I

Indexed keywords

BINDING PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; TISSUE LEVEL;

EID: 0031807950     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816060-00018     Document Type: Article

References (49)

1. Van den Brande JL, Hoogerbrugge CM, Beyreuther K, Roepstorff P, Jansen J, van Buul-Offers SC. Isolation and partial characterization of IGF-like peptides from Cohn fraction IV of human plasma. Acta Endocrinol 1990; 122:683-695.
2. Le Roith D. Insulin-like growth factors. W Engl J Med 1997; 336:633-640.
3. Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocrinol Rev 1995; 16:117-142.
4. Nyomba BLG, Berard L, Murphy LJ. Free insulin-like growth factor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity J Clin Endocrinol Metab 1997; 82:2177-2181.
5. Frystyk J, Skjærbæk C, Dinesen B, Orskov H, Free insulin-like growth factor (IGF-I and IGF-II) in human serum. FEBS Lett 1994; 348:185-191.
6. Jones JI. Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrinol Rev 1995; 16:3-34.
7. Drop SLS. Schuller AGP, Lindenbergh-Kortleve DJ. Structural aspects of the IGFBP family. Growth Regul 1992; 2:69-79.
8. Hodgkinson S, Spencer G, Bass J, Davis S, Gluckman P: Distribution of circulating insulin-like growth factor-I (IGF-I) into tissues. Endocrinology 1991; 129:2085-2093.
9. Hardouin S, Gourmelen M, Noguiez P, Seurin D, Roghani M, Le Buc Y, et al. Molecular forms of serum-insulin-like growth factor (IGF)-binding proteins in man: relationships with growth hormone and IGFs and physiological significance. J Clin Endocrinol Metab 1989; 69:1291-1301.
10. Sowers JR. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997; 29:691-699.
11. Laviades C, Mayor G, Diez J. Elevated circulating levels of insulin-like growth factor I in essential hypertensive patients with left ventricular hypertrophy. Arch Mal Cœur 1991; 84:1039-1041.
12. Andronico G, Mangano M-T, Nardi E, Mulé G, Piazza G, Cerasola G. Insulin-like growth factor I and sodium-lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy. J Hypertens 1993; 11:1097-1101.
13. Diez J, Laviades C, Martinez E, Gil MJ, Monreal I, Fernández J, et al. Insulin-like growth factor binding proteins in arterial hypertension: relationship to left ventricular hypertrophy. J Hypertens 1995; 13:349-355.
14. Laviades C, Gil MJ, Monreal I, González A, Diez J. Is the tissue availability of circulating insulin-like growth factor I involved in organ damage and glucose regulation in hypertension? J Hypertens 1997; 15:1159-1165.
15. Turner RC, Holman RR, Matthews DR, Hockaday TDR, Peto J. Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal insulin and glucose concentrations. Metabolism 1979; 28:1086-1096.
16. Turner RC, Matthews DR, Holman RR, Peto J. Relative contributions of insulin deficiency and insulin resistance in maturity-onset diabetes. Lancet 1982, i:596-598.
17. Hosker JP, Matthews DR, Rudenski AS, Burnett MA, Darling P, Bown EG, et al. Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta cell function in man. Diabetologia 1985; 28:401-411.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
19. WHO. Hypertension control. Report of a WHO Expert Committee. Geneva: WHO; 1996.
20. Blumenfeld JD, Mann SJ, Laragh JH. Clinical evaluation and differential diagnosis of the individual hypertensive patient. In: Laragh JH, Brenner BM. Hypertension: pathophysiology, diagnosis, and management. Second edition New York: Raven Press; 1995, pp. 1897-1912.
21. Chang-deMoranville BM, Jackson IMD. Diagnosis and endocrine testing in acromegaly. Endocrinol Metab Clin North Am 1992; 21:649-668.
22. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39:167-174.
23. Reaven GM. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension: parallels between human disease and rodent models. Diabetes Care 1991; 14:195-202.
24. Bondy CA, Underwood LE, Clemmons DR, Guler HP, Bach MA, Skarulis M. Clinical uses of insulin-like growth factor I. Ann Intern Med 1994; 120:593-601.
25. Schenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER. Recombinant human insulin-like growth factor I (rhIGF-I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia 1991; 34:675-679.
26. Quin JD, Fisher BM, Paterson KR, Inoue A, Beastall GH, MacCuish AC. Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall's syndrome. W Engl J Med 1990; 323:1425-1426.
27. Moses AC, Morrow LA, O'Brien M, Moller DE, Flier JS. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract 1995; 28 (suppl):5185-5194.
28. Kuzuya H, Matsuura N, Sakamoto M. Trial of insulin-like growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 1993; 42:696-705.
29. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER. Insulin-tike growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992; 90:2234-2241.
30. Moses AC, Young SCJ, Morrow LA, O'Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996; 45:91-100.
31. Lewitt MS, Denyer OS, Cooney GJ, Baxter RC. Insulin-like growth factor-binding protein-I modulates blood glucose levels. Endocrinology 1991; 129:2254-2256.
32. Dai Z, Xing Y, Boney CM, Clemmons DR, D'Ercole J. Human insulin-like growth factor-binding protein-I (hIGFBP-I) in transgenic mice: characterization and insights into the regulation of IGFBP-I expression. Endocrinology 1994; 135:1316-1327.
33. Baxter RC. Insulin-like growth factor binding proteins as glucoregulators. Metabolism 1995; 44 (suppl 4):12-17.
34. Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Verricchio M. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 1992; 6:175-179.
35. Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomano F, et al. Lisinopril administration improves insulin action in aged patients with hypertension. J Hum Hypertens 1995; 9:541-546.
36. Fogari R, Lusardi P, Corradi L, Zoppi A, Lazzari P, Preti P, et al. Effects of lisinopril and losartan on insulin sensitivity in non diabetic hypertensive patients [abstract]. Am J Hypertens 1996; 9:152.
37. Zehetgruber M, Beckmann R, Gabriel H. The ACE-inhibitor lisinopril affects plasma insulin levels but not fibrinolytic parameters. Thromb Res 1996; 83:143-152.
38. Chen Y-D, Maheux P, Jeppesen J, Barghava R, Reaven GM. Comparative effects of lisinopril and low-dose diuretic treatment on blood pressure and glucose, insulin and lipoprotein metabolism in obese hypertensives [abstract]. Am J Hypertens 1994; 7:12A.
39. Thürig C, Bohlen L, Schneider M, de Courten M, Shaw SG, Riesen W, et al. Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients. Eur J Clin Pharmacol 1995; 49:21-26.
40. Sowers JR, Nyby M, Stern N, Beck F, Baron S, Catania R, et al. Blood pressure and hormone changes associated with weight reduction in the obese. J Hypertens 1982; 4:686-691.
41. Reaven GM. Pathophysiology of insulin resistance in humans. Physiol Rev 1995; 75:473-486.
42. Douglas JG, Brown GP, White C. Angiotensin II receptors of human and primate adrenal fasciculata and glomerulosa: correlations of binding and steroidogenesis. Metabolism 1984; 33:685-688.
43. Bonora E, Targher G, Alberiche M. Intracellular partitioning of glucose metabolism in type 2 diabetic subjects with and without hypertension, before and after treatment with lacidipine or lisinopril [abstract]. Diabetologia 1996; 1:A36.
44. Hall K, Brismar K, Grissom F, Lindgren B, Póvoa G. IGFBP-1. Production and control mechanisms. Acta Endocrinol 1991; 124 (suppl 2):48-54.
45. Holly JMP. The physiological role of IGFBP-1. Acta Endocrinol 1991; 124 (suppl 2):55-62.
46. Senevirante C, Luo J, Murphy U. Transcriptional regulation of rat insulin-like growth factor binding protein-I expression by growth hormone. Mol Endocrinol 1990; 4:1199-1204.
47. Conover CA, Divertie GD, Lee PDK. Cortisol increases plasma insulin-like growth factor binding protein-1 in humans. Acta Endocrinol 1989; 128:140-143.
48. Lewitt MS, Baxter RC. Regulation of growth hormone-independent insulin-like growth factor binding protein (BP-28) in cultured human fetal liver expiants. J Clin Endocrinol Metab 1989; 69:246-252.
49. Lee PDK, Conover CA, Powell DR. Regulation and function of insulin-like growth factor-binding protein-1. Proc Soc Exp Biol Med 1993; 204:4-29.